4//SEC Filing
AVANIR PHARMACEUTICALS, INC. 4
Accession 0001209191-14-076513
CIK 0000858803operating
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 8:52 AM ET
Size
18.5 KB
Accession
0001209191-14-076513
Insider Transaction Report
Form 4
Katkin Keith
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2014-12-15$1.74/sh+139,200$242,208→ 1,115,969 total - Sale
Common Stock
2014-12-15$16.95/sh−195,160$3,307,962→ 976,769 total - Sale
Common Stock
2014-12-17$16.93/sh−62,520$1,058,464→ 914,249 total - Exercise/Conversion
Stock Option (right to buy)
2014-12-15−55,960→ 976,769 totalExercise: $1.29Exp: 2017-03-21→ Common Stock (55,960 underlying) - Sale
Common Stock
2014-12-15$16.95/sh−20,000$339,000→ 976,769 total - Exercise/Conversion
Common Stock
2014-12-15$1.29/sh+55,960$72,188→ 1,171,929 total - Exercise/Conversion
Stock Option (right to buy)
2014-12-15−139,200→ 976,769 totalExercise: $1.74Exp: 2019-11-27→ Common Stock (139,200 underlying)
Footnotes (7)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Action of 1934, as amended. A portion of the proceeds from the sales will be used to pay required withholdings due by the Reporting Person for vesting RSUs. Following the sales reported on this Form 4, the Reporting Person has a total of 1,278,556 options to purchase shares of common stock that are vested and immediately exercisable and a total of 290,625 options to purchase shares of common stock that have not yet vested. Following the sales reported on this Form 4, the Reporting Person also has 734,202 unvested Restricted Stock Units, of which 140,611 are performance-based Restricted Stock Units.
- [F2]Represents the weighted-average price at which shares were sold within a range between $16.905 and 16.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F3]Includes previously reported shares of common stock underlying Restricted Stock Grants granted to the Reporting Person, which are subject to certain vesting conditions.
- [F4]Represents the weighted-average price at which shares were sold within a range between $16.89 and 16.98. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F5]Represents the weighted-average price at which shares were sold within a range between $16.93 and 16.935. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F6]The option was granted on 3/21/2007 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.
- [F7]The option was granted on 11/27/2009 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.
Documents
Issuer
AVANIR PHARMACEUTICALS, INC.
CIK 0000858803
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000858803
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 8:52 AM ET
- Size
- 18.5 KB